Literature DB >> 26538609

Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys.

Annaelle Devergnas1, Erdong Chen2, Yuxian Ma2, Ikuma Hamada2, Damien Pittard2, Stefan Kammermeier3, Ariana P Mullin4, Victor Faundez5, Craig W Lindsley6, Carrie Jones6, Yoland Smith7, Thomas Wichmann7.   

Abstract

Conventional anti-Parkinsonian dopamine replacement therapy is often complicated by side effects that limit the use of these medications. There is a continuing need to develop nondopaminergic approaches to treat Parkinsonism. One such approach is to use medications that normalize dopamine depletion-related firing abnormalities in the basal ganglia-thalamocortical circuitry. In this study, we assessed the potential of a specific T-type calcium channel blocker (ML218) to eliminate pathologic burst patterns of firing in the basal ganglia-receiving territory of the motor thalamus in Parkinsonian monkeys. We also carried out an anatomical study, demonstrating that the immunoreactivity for T-type calcium channels is strongly expressed in the motor thalamus in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. At the electron microscopic level, dendrites accounted for >90% of all tissue elements that were immunoreactive for voltage-gated calcium channel, type 3.2-containing T-type calcium channels in normal and Parkinsonian monkeys. Subsequent in vivo electrophysiologic studies in awake MPTP-treated Parkinsonian monkeys demonstrated that intrathalamic microinjections of ML218 (0.5 μl of a 2.5-mM solution, injected at 0.1-0.2 μl/min) partially normalized the thalamic activity by reducing the proportion of rebound bursts and increasing the proportion of spikes in non-rebound bursts. The drug also attenuated oscillatory activity in the 3-13-Hz frequency range and increased gamma frequency oscillations. However, ML218 did not normalize Parkinsonism-related changes in firing rates and oscillatory activity in the beta frequency range. Whereas the described changes are promising, a more complete assessment of the cellular and behavioral effects of ML218 (or similar drugs) is needed for a full appraisal of their anti-Parkinsonian potential.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  Parkinsonism; T-type calcium channel; nondopaminergic therapy; rebound burst

Mesh:

Substances:

Year:  2015        PMID: 26538609      PMCID: PMC4760490          DOI: 10.1152/jn.00858.2015

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  81 in total

Review 1.  Bursting of thalamic neurons and states of vigilance.

Authors:  Rodolfo R Llinás; Mircea Steriade
Journal:  J Neurophysiol       Date:  2006-03-22       Impact factor: 2.714

Review 2.  The control of retinogeniculate transmission in the mammalian lateral geniculate nucleus.

Authors:  S M Sherman; C Koch
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

3.  Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1.

Authors:  Avanti Gokhale; Jennifer Larimore; Erica Werner; Lomon So; Andres Moreno-De-Luca; Christa Lese-Martin; Vladimir V Lupashin; Yoland Smith; Victor Faundez
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

4.  T-type calcium channels consolidate tonic action potential output of thalamic neurons to neocortex.

Authors:  Charlotte Deleuze; François David; Sébastien Béhuret; Gérard Sadoc; Hee-Sup Shin; Victor N Uebele; John J Renger; Régis C Lambert; Nathalie Leresche; Thierry Bal
Journal:  J Neurosci       Date:  2012-08-29       Impact factor: 6.167

5.  GABAergic inputs from direct and indirect striatal projection neurons onto cholinergic interneurons in the primate putamen.

Authors:  Kalynda Kari Gonzales; Jean-Francois Pare; Thomas Wichmann; Yoland Smith
Journal:  J Comp Neurol       Date:  2013-08-01       Impact factor: 3.215

6.  Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients.

Authors:  M Magnin; A Morel; D Jeanmonod
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats.

Authors:  Hideto Miwa; Jinsoo Koh; Yoshinori Kajimoto; Tomoyoshi Kondo
Journal:  Pharmacol Biochem Behav       Date:  2010-11-26       Impact factor: 3.533

8.  Ultrastructural relationships between cortical, thalamic, and amygdala glutamatergic inputs and group I metabotropic glutamate receptors in the rat accumbens.

Authors:  D A Mitrano; J-F Pare; Y Smith
Journal:  J Comp Neurol       Date:  2010-04-15       Impact factor: 3.215

9.  Differences in neuronal firing rates in pallidal and cerebellar receiving areas of thalamus in patients with Parkinson's disease, essential tremor, and pain.

Authors:  G F Molnar; A Pilliar; A M Lozano; J O Dostrovsky
Journal:  J Neurophysiol       Date:  2005-02-09       Impact factor: 2.714

10.  Axon initial segment Ca2+ channels influence action potential generation and timing.

Authors:  Kevin J Bender; Laurence O Trussell
Journal:  Neuron       Date:  2009-01-29       Impact factor: 17.173

View more
  11 in total

Review 1.  Calcium signals that determine vascular resistance.

Authors:  Matteo Ottolini; Kwangseok Hong; Swapnil K Sonkusare
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2019-03-18

2.  NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate.

Authors:  Subhrajit Bhattacharya; Yuxian Ma; Amy R Dunn; Joshua M Bradner; Annalisa Scimemi; Gary W Miller; Stephen F Traynelis; Thomas Wichmann
Journal:  J Neurosci Res       Date:  2018-03-25       Impact factor: 4.164

3.  Delta oscillations are a robust biomarker of dopamine depletion severity and motor dysfunction in awake mice.

Authors:  Timothy C Whalen; Amanda M Willard; Jonathan E Rubin; Aryn H Gittis
Journal:  J Neurophysiol       Date:  2020-06-24       Impact factor: 2.714

4.  Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Allison Weinkle; Stella M Papa; Yoland Smith
Journal:  Cereb Cortex       Date:  2022-04-20       Impact factor: 4.861

5.  Structural plasticity of GABAergic and glutamatergic networks in the motor thalamus of parkinsonian monkeys.

Authors:  Ashley J Swain; Adriana Galvan; Thomas Wichmann; Yoland Smith
Journal:  J Comp Neurol       Date:  2019-12-16       Impact factor: 3.215

6.  Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys.

Authors:  Adriana Galvan; Annaelle Devergnas; Damien Pittard; Gunasingh Masilamoni; Jocelyn Vuong; J Scott Daniels; Ryan D Morrison; Craig W Lindsley; Thomas Wichmann
Journal:  ACS Chem Neurosci       Date:  2016-09-20       Impact factor: 4.418

7.  Changes in Excitability Properties of Ventromedial Motor Thalamic Neurons in 6-OHDA Lesioned Mice.

Authors:  Edyta K Bichler; Francesco Cavarretta; Dieter Jaeger
Journal:  eNeuro       Date:  2021-02-24

8.  Sub-synaptic localization of Cav3.1 T-type calcium channels in the thalamus of normal and parkinsonian monkeys.

Authors:  Erdong Chen; Jean-Francois Paré; Thomas Wichmann; Yoland Smith
Journal:  Brain Struct Funct       Date:  2016-06-02       Impact factor: 3.270

9.  Thalamic control of cortical dynamics in a model of flexible motor sequencing.

Authors:  Laureline Logiaco; L F Abbott; Sean Escola
Journal:  Cell Rep       Date:  2021-06-01       Impact factor: 9.423

Review 10.  Pathophysiological roles and therapeutic potential of voltage-gated ion channels (VGICs) in pain associated with herpesvirus infection.

Authors:  Qiaojuan Zhang; Miguel Martin-Caraballo; Shaochung V Hsia
Journal:  Cell Biosci       Date:  2020-05-24       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.